Clinical Trial Detail

NCT ID NCT03072160
Title Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

thyroid gland medullary carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.